Digest Network Come funziona
Network
/
Società
En
Non verificato

Enanta Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaHIV, AIDS e malattie autoimmuniMedicina - VarieSalute

38 comunicati stampa

Guarda tutti i comunicati
03/03/2026
Web e Social Network
Eventi
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
10/02/2026
Salute
HIV, AIDS e malattie autoimmuni
Biotecnologia
Sanità
Medicina - Varie
Farmaceutica
Eventi
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
09/02/2026
Eventi
Mercato azionario
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
08/01/2026
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Web e Social Network
Eventi
Industria
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
05/01/2026
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Web e Social Network
Eventi
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
17/11/2025
Mercato azionario
Salute
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Farmaceutica
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
04/11/2025
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
20/10/2025
Salute
HIV, AIDS e malattie autoimmuni
Biotecnologia
Sanità
Medicina - Varie
Farmaceutica
Eventi
Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
07/10/2025
Scienza
Biotecnologia
Farmaceutica
Salute
HIV, AIDS e malattie autoimmuni
Sanità
Eventi
Industria
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
02/10/2025
Scienza
Biotecnologia
Farmaceutica
Finanza
Salute
Associazioni/Professionisti
Medicina - Varie
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0